Home / Business and Economy / Sudeep Pharma IPO: Pharma Giant Seeks ₹95 Cr Capex
Sudeep Pharma IPO: Pharma Giant Seeks ₹95 Cr Capex
21 Nov
Summary
- Sudeep Pharma plans ₹95 crore capex and ₹800 crore offer for sale.
- Manufacturing capacity to increase to 1.2 lakh tonnes by March 2026.
- Company revenue grew 5% and net profit jumped 30.6% between FY23-FY25.
Sudeep Pharma, a prominent player in pharmaceutical excipients and specialty nutrition, is preparing for an Initial Public Offering. The company aims to raise ₹95 crore through a fresh issue to fund significant capital expenditure, alongside an offer for sale amounting up to ₹800 crore. This expansion plan includes a substantial increase in manufacturing capacity, targeting 1.2 lakh tonnes by the end of March 2026.
The Vadodara-based company, established in 1989, operates three plants in Gujarat and has expanded internationally with a facility in Ireland. It boasts a diverse portfolio of over 100 products and is recognized as one of India's leading exporters of mineral ingredients for pharma excipients and nutritional ingredients. Approximately 60% of its revenue is derived from exports to about 100 countries.
Financially, Sudeep Pharma has shown positive performance, with revenue growing 5% to ₹502 crore and net profit surging 30.6% to ₹138.7 crore between FY23 and FY25. The company also reported a substantial increase in Ebitda and an improved Ebitda margin, alongside a marginal increase in return on capital employed.
